ClinicalTrialsFinder
RecruitingNCT02325674

MEASuRE: Metreleptin Effectiveness And Safety Registry

Sponsor

Amryt Pharma

Enrollment

100 participants

Start Date

Oct 11, 2016

Study Type

OBSERVATIONAL

Conditions

Partial LipodystrophyGeneralised Lipodystrophy

Summary

The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.

Eligibility

Inclusion Criteria3

  • Patients treated with metreleptin through commercial supply at the time or before enrolment into registry
  • Patients who provide a written consent
  • Patient coming off metreleptin clinical studies and continuing or restarting treatment with metreleptin through commercial supply

Exclusion Criteria1

  • • Patients currently treated with an investigational agent as part of a clinical trial
Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMetreleptin

Locations(28)

University Alabama at Birmingham

Birmingham, Alabama, United States

City of Hope

Duarte, California, United States

Atlanta Diabetes Associates

Atlanta, Georgia, United States

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

University of Kansas Medical Center Research Institute, Inc.

Kansas City, Kansas, United States

Children's Hospital of New Orleans/LSU Health Sciences Center

New Orleans, Louisiana, United States

Ochsner Clinic Foundation

New Orleans, Louisiana, United States

Nih/Niddk/Deob

Bethesda, Maryland, United States

University of Michigan

Ann Arbor, Michigan, United States

Childrens Hospital of Michigan

Detroit, Michigan, United States

Richmond University Medical Centre

Staten Island, New York, United States

Endocrinology Research Associates

Columbus, Ohio, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

UT Southwestern Medical Center

Dallas, Texas, United States

Seattle Children's Hospital

Seattle, Washington, United States

CHRU Hôpital Claude Huriez

Lille, Nord, France

Hôpital Robert Debré

Paris, Paris, France, France

Hôpital Saint-Antoine

Paris, France

Universitaetsklinikum Ulm

Ulm, Baden-Wurttemberg, Germany

Kinderkrankenhaus Auf der Bult

Hanover, Lower Saxony, Germany

Universitaetsklinikum Muenster

Münster, North Rhine-Westphalia, Germany

Universitaetsklinikum Leipzig AoeR

Leipzig, Saxony, Germany

Universita del Piemonte Orientale "Amedeo Avogadro"

Novara, Verceilli, Italy

Alma Mater Studiorum - Università di Bologna

Bologna, Italy

Azienda Ospedaliero Universitaria Pisana (Presidio di Cisanello)

Pisa, Italy

Azienda Ospedaliera Universitaria Policlinico Tor Vergata

Roma, Italy

Addenbrooke's Hospital

Cambridge, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02325674

Related Trials

Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance

NCT054705041 location

Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

NCT0648486812 locations